ZYVERSA THERAPEUTICS, INC. Interest Income (Expense), Net
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Interest Income (Expense), Net of -$132.51 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement
us-gaap:InterestIncomeExpenseNet · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2026-03-31 was -$132.51K.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2025-12-31 was -$132.26K.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2025-09-30 was -$131.35K.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2025-06-30 was -$130.04K.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for fiscal 2025 was -$513.21K.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for fiscal 2024 was -$269.86K, a 59149.45% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. interest income (expense), net for fiscal 2023 was $457.00.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 11 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$132.51K 10-Q · filed 2026-05-13 | -$264.77K derived: sum of 2 quarters · filed 2026-05-13 | -$396.13K derived: sum of 3 quarters · filed 2026-05-13 | -$526.16K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-12-31 | -$132.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$263.61K derived: sum of 2 quarters · filed 2026-03-31 | -$393.65K derived: sum of 3 quarters · filed 2026-03-31 | -$513.21K 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$131.35K 10-Q · filed 2025-11-19 | -$261.39K derived: sum of 2 quarters · filed 2025-11-19 | -$380.95K 10-Q · filed 2025-11-19 | -$519.01K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-06-30 | -$130.04K 10-Q · filed 2025-08-13 | -$249.60K 10-Q · filed 2025-08-13 | -$387.66K derived: sum of 3 quarters · filed 2026-05-13 | -$519.29K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-03-31 | -$119.56K 10-Q · filed 2026-05-13 | -$257.62K derived: sum of 2 quarters · filed 2026-05-13 | -$389.26K derived: sum of 3 quarters · filed 2026-05-13 | -$389.31K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$138.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$269.70K derived: sum of 2 quarters · filed 2026-03-31 | -$269.75K derived: sum of 3 quarters · filed 2026-03-31 | -$269.86K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$131.63K 10-Q · filed 2025-11-19 | -$131.69K derived: sum of 2 quarters · filed 2025-11-19 | -$131.79K 10-Q · filed 2025-11-19 | -$131.89K derived: sum of 4 quarters · filed 2025-11-19 | |
| 2024-06-30 | -$58.00 10-Q · filed 2025-08-13 | -$159.00 10-Q · filed 2025-08-13 | -$257.00 derived: sum of 3 quarters · filed 2025-08-13 | -$467.00 derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$101.00 10-Q · filed 2025-05-12 | -$199.00 derived: sum of 2 quarters · filed 2025-05-12 | -$409.00 derived: sum of 3 quarters · filed 2025-05-12 | -$723.00 derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$98.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$308.00 derived: sum of 2 quarters · filed 2025-03-27 | -$622.00 derived: sum of 3 quarters · filed 2025-03-27 | $457.00 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$210.00 10-Q · filed 2024-11-14 | -$524.00 derived: sum of 2 quarters · filed 2024-11-14 | $555.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$314.00 10-Q · filed 2024-08-09 | $765.00 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $1.08K 10-Q · filed 2024-05-15 | ||||
| 2022-12-12 | -$427.54K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |